Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
20 c » 2 c (Expand Search), 20 _ (Expand Search), 25 c (Expand Search)
Showing 501 - 520 results of 70,687 for search '(( 20 c decrease ) OR ( 5 ((((a decrease) OR (mean decrease))) OR (we decrease)) ))', query time: 1.16s Refine Results
  1. 501
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 502
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 503
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 504
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 505
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 506
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 507
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 508
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 509
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 510
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 511
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 512
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 513
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 514
    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each combination of drill system (MIPS and MONO) and drilling protocol (DP1-DP5).

    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... by Marsel Ganeyev (21453399)

    Published 2025
    Save to List
    Saved in:
  15. 515
    Quantitative analysis.

    Quantitative analysis. by Miao Cheng (4348510)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 516
    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX

    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

    Published 2022
    “…</p><p>Methods: We applied Agena MassARRAY technology platform to genotype five single nucleotide polymorphisms (SNPs) located in CLEC16A in 1004 controls and 995 cases. …”
    Save to List
    Saved in:
  17. 517
    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX

    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

    Published 2022
    “…</p><p>Methods: We applied Agena MassARRAY technology platform to genotype five single nucleotide polymorphisms (SNPs) located in CLEC16A in 1004 controls and 995 cases. …”
    Save to List
    Saved in:
  18. 518
    Decreasing Structural Dimensionality of Double Perovskites for Phase Stabilization toward Efficient X‑ray Detection

    Decreasing Structural Dimensionality of Double Perovskites for Phase Stabilization toward Efficient X‑ray Detection by Da Chen (585723)

    Published 2021
    Save to List
    Saved in:
  19. 519
    Decreasing Structural Dimensionality of Double Perovskites for Phase Stabilization toward Efficient X‑ray Detection

    Decreasing Structural Dimensionality of Double Perovskites for Phase Stabilization toward Efficient X‑ray Detection by Da Chen (585723)

    Published 2021
    Save to List
    Saved in:
  20. 520
    Effects of NMRAL1 siRNA transfection on the expression of inflammatory cytokines in RAW264.7 macrophages.

    Effects of NMRAL1 siRNA transfection on the expression of inflammatory cytokines in RAW264.7 macrophages. by Miao Cheng (4348510)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: